Taxonomy Code 1835X0200X(1835x0200x)
Oncology Pharmacist. Providers: 40
Select City
B
G
H
N
W
Oncology Pharmacist Providers
| NPI | Name | Type | Address |
|---|---|---|---|
|
Brenda Yik |
Individual |
55 Park St New Haven, CT |
|
|
Paul Joseph Piazza |
Individual |
267 Grant St Bridgeport, CT |
|
|
PHARMD Sara Mohamed Jaszczur |
Individual |
55 Park St New Haven, CT |
|
|
Jennifer Chen Zhao |
Individual |
55 Park St New Haven, CT |
|
|
DR. PHARMD Trinh Pham |
Individual |
55 Park St New Haven, CT |
|
|
PHARMD Kejal Amin |
Individual |
111 Goose Ln Guilford, CT |
|
|
PHARMD Laura Tuttle |
Individual |
55 Park St New Haven, CT |
|
|
Ying Long |
Individual |
55 Park St New Haven, CT |
|
|
PHARM.D Xiaohong Zhang |
Individual |
55 Park St New Haven, CT |
|
|
Randa Adib Chaar |
Individual |
55 Park St New Haven, CT |
|
|
PHARMD Rebecca Abramovitz |
Individual |
55 Park St Smilow Oncology Pharmacy New Haven, CT |
|
|
Arkadiusz W Stobierski |
Individual |
55 Park St New Haven, CT |
|
|
DR. PHARMD Jessica Noel Leclair |
Individual |
55 Park Street Yale New Haven Hospital New Haven, CT |
|
|
PHARMD Aubrey Johnson |
Individual |
55 Park St New Haven, CT |
|
|
PHARMD Katherine Joyce Lin |
Individual |
55 Park St New Haven, CT |
|
|
Jamie M Blanck |
Individual |
55 Park St New Haven, CT |
|
|
Laura Holley |
Individual |
55 Park St New Haven, CT |
|
|
PHARMD Jason Jesus Casazola |
Individual |
35 Park St New Haven, CT |
|
|
PHARMD Man Yee Merl |
Individual |
20 York St New Haven, CT |
|
|
PHARMD Marijana Stefanovic |
Individual |
77 Lafayette Pl Greenwich, CT |
How to obtain, renew, or terminate an NPI
Every health care provider, whether it’s a hospital, pharmacy, or individual specialist, must obtain their own NPI number. This identification number is unique and is assigned upon application. In tod...
| Taxonomy Code | 1835X0200X |
| Specialization | Oncology |
| Display Name | Oncology Pharmacist |
| Taxonomy Group | Pharmacy Service Providers |
| Taxonomy Classification | Pharmacist |
| Definition | A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases. |
| Effective Date | September 30, 2009 |